Skip to content
1st Counsel – Lifestyle
Author:
Onward Therapeutics, Inc.
Onward Therapeutics Closes NT$900 Million (approximately US$28 Million) Series B Financing to Advance Clinical-Stage Oncology Pipeline
November 17, 2026